Off-label gabapentin (Neurontin) got a bad rep when it missed the mark in bipolar disorder, but there may be something worth salvaging in this drug. Here, we weigh its pros and cons for anxiety, substance use disorders, sleep, pain, and hot flashes, and compare it to its underutilized cousin, pregabalin (Lyrica).
Read More
Dr. Miller discusses new options for negative symptoms, how to improve the therapeutic alliance, and what to do when clozapine doesn’t work in schizophrenia.
Read More
MDMA is being repurposed as part of drug-assisted psychotherapy for PTSD, and this trial will help determine whether it gains FDA approval for that use.
Read More
In December 2021, the FDA approved lumateperone (Caplyta) for bipolar I and II depression, and here we report on one of the trials that led to that approval.
Read More
With so few pharmacologic options for methamphetamine use disorder, a large trial from The New England Journal of Medicine suggest bupropion and naltrexone are worth exploring.
Read More
Lybalvi hopes to lower the risk of weight gain on olanzapine by combining it with an opioid blocker (samidorphan). But how does it compare to generic options like metformin and naltrexone?
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
